Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07645300 · ClinicalTrials.gov registry record · Phase 2
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
A Phase 2 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07645300: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT07645300 is a Phase 2 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07645300, a Phase 2 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Interventions
- DRUG phase 2A Chlorthalidone
- DRUG phase 2A Spironolactone
- DRUG phase 2A Chlorthalidone + Spironolactone
- DRUG phase 2B Chlorthalidone LD + Spironolactone LD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07645300
The ClinicalTrials.gov registry entry for NCT07645300 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which phase 2A Chlorthalidone is the first listed.
NCT07645300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07645300 about?
NCT07645300 is a clinical study titled "LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial". The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high...
What is the current status of trial NCT07645300?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-10-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT07645300?
The interventions under investigation include: phase 2A Chlorthalidone (DRUG), phase 2A Spironolactone (DRUG), phase 2A Chlorthalidone + Spironolactone (DRUG), phase 2B Chlorthalidone LD + Spironolactone LD (DRUG).
Who is sponsoring clinical trial NCT07645300?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.